TABLE 1.
HFS-TB derived drug exposure target and susceptibility breakpoint MIC of drugs with antimycobacterial activity.
| Drug | PK/PD target | Susceptibility breakpoint (mg/L) | References |
|---|---|---|---|
| Amikacin | Cmax/MIC >10.13 | Srivastava et al. (2016a) | |
| Cefazolin | %T > MIC = 46.76 | 1–2 | Srivastava et al. (2021c) |
| Cefdinir | AUC0-24/MIC = 578.86 | Srivastava et al. (2021d) | |
| Ceftriaxone | %T > MIC = 68 | Srivastava et al. (2020) | |
| Cycloserine | %T > MIC = 30 | Deshpande et al. (2018a) | |
| Delamanid | AUC0-24/MIC = 195 | Mallikaarjun et al. (2021) | |
| Ertapenem | %T > MIC >40 | 2 | van Rijn et al. (2017) |
| Ethambutol | Cmax/MIC >0.51 | 4 | Srivastava et al. (2010) |
| Ethionamide | AUC0-24/MIC >56.2 | 2.5 | Deshpande et al. (2018c) |
| Faropenem | %T > MIC >62 | Deshpande et al. (2016) | |
| Gatifloxacin | AUC0-24/MIC >184 | 0.5 | Deshpande et al. (2018d) |
| Isoniazid | AUC0-24/MIC >567 | 0.0312 | Gumbo et al. (2007c) |
| Levofloxacin | AUC0-24/MIC >146 | 0.5 | Deshpande et al. (2018b) |
| Linezolid | AUC0-24/MIC >119 | 2 | Srivastava et al. (2017) |
| Minocycline | AUC0-24/MIC = 71.58 | 8 | Deshpande et al. (2019b) |
| Moxifloxacin | AUC0-24/MIC >56 | 1 | Gumbo et al. (2004) |
| Penicillin | %T > MIC >65 | Deshpande et al. (2018e) | |
| Pyrazinamide | AUC0-24/MIC >209 | 50 | Gumbo et al. (2009) |
| Rifampin | AUC0-24/MIC >1,360 | 0.0625 | (Gumbo et al., 2007a; Gumbo, 2010) |
| Tedizolid | AUC0-24/MIC >200 | 0.5 | Srivastava et al. (2018) |
| Thioridazine | AUC0-24/MIC = 50.53 | Musuka et al. (2013) | |
| Tigecycline | AUC0-24/MIC >42.3 | Deshpande et al. (2019a) | |
| Vancomycin | AUC0-24/MIC = 2,954 | Srivastava et al. (2021a) |
Drugs are arranged in alphabetical order. MIC, minimum inhibitory concentration; Cmax, peak concentration; AUC, area under the concentration-time curve; %T > MIC, percentage of time drug concentration persist above MIC.